| ovarian site | pelvic site | pelvic site + ovarian site | heterotopic transplantation |
---|---|---|---|---|
CLBR | 21(6–40, I2: 52.81%)** | 30(20–40, I2: 0.00%)* | 23(11–36, I2: 0.00%)* | 3(0–17, I2: 0.00%)* |
Spontaneous LBR | 16(3–35, I2: 0.00%)* | 31(21–42, I2: 0.00%)* | 26(12–41, I2: 0.00%)* | 0 |
LBR after IVF | 10(2–22, I2: 0.00%)* | 18(7–31, I2: 0.00%)* | 5(0–27, I2: 0.00%)* | 3(0–17, I2: 0.00%)* |
Women with at least one pregnancy after IVF and spontaneous pregnancy | 25(13–40, I2: 0.00%)* | 42(22–63, I2: 65.30%)** | 25(13–38, I2: 0.00%)* | 7(0–24, I2: 0.00%)* |
Women with at least one spontaneous pregnancy | 26(9–46, I2: 0.00%)* | 32(14–54, I2: 70.92%)** | 38(10–71, I2: 60.46%)** | 0 |
Women with at least one pregnancy after IVF | 9(0–25, I2: 0.00%)* | 28(7–54, I2: 65.63%)** | 15(0–40, I2: 0.00%)* | 7(0–24, I2: 0.00%)* |
Women with miscarriage after IVF and spontaneous pregnancy | 10(2–21, I2: 0.00%)* | 11(0–27, I2: 62.34%)** | 8(1–18, I2: 0.00%)* | 7(0–23, I2: 0.00%)* |
Women with miscarriage after spontaneous pregnancy | 5(0–19, I2: 0.00%)* | 12(0–33, I2: 77.90%)** | 3(0–12, I2: 0.00%)* | 0 |
Women with miscarriage after IVF | 0(0–9, I2: 0.00%)* | 14(2–30, I2: 0.00%)* | 15(0–40, I2: 0.00%)* | 7(0–23, I2: 0.00%)* |